What is the market's earnings forecast for Ocular Therapeutix next quarter?

What were the key takeaways from Ocular Therapeutix’s earnings call?

What is the revenue and EPS growth rate for Ocular Therapeutix year over year?

What does Ocular Therapeutix do and what are its main business segments?

Did Ocular Therapeutix beat or miss consensus estimates last quarter?

What factors drove the changes in Ocular Therapeutix's revenue and profit?

What guidance did Ocular Therapeutix's management provide for the next earnings period?

What were the key takeaways from Ocular Therapeutix's earnings call?

- **Wet AMD Milestone**: SOL-R trial reaches 555-subject randomization, with SOL-1 on track for Q1 2026 data, targeting a superiority label.
- **DR Breakthrough**: HELIOS program uses ordinal DRSS endpoint, aiming for a broad label covering NPDR and DME, with single injection lasting 12 months.
- **Financial Security**: $445M equity financing extends cash runway to 2028, supporting clinical and commercial efforts.
- **Strategic Triad**: Superiority, market expansion (untreated NPDR patients), and seamless integration into existing workflows drive differentiation.

**【Management Opening Remarks】**
- William Slattery provided an overview of the call, referencing the press release and Q3 2025 financial results, including updates on AXPAXLI's registrational programs in wet AMD and non-proliferative diabetic retinopathy (NPDR). He highlighted the availability of the full report on the company's Investor Relations website.

**【CEO Commentary】**
- **Wet AMD Progress**: SOL-1 Phase III superiority trial remains on track for Q1 2026 top-line data. SOL-R, a non-inferiority trial, reached target randomization of 555 subjects, with a unique 6-month screening/loading phase to exclude high-risk patients. SOL-X, a long-term extension study, will evaluate 6-month dosing intervals and long-term outcomes.
- **Diabetic Retinopathy (DR) Strategy**: The HELIOS program aims for a broad label encompassing NPDR and DME. HELIOS-2 (6-month dosing) and HELIOS-3 (12-month dosing) use an ordinal DRSS endpoint, capturing improvement, stability, and worsening. This design increases statistical power and aligns with FDA guidance.
- **Financial Strength**: $345M cash on hand (excluding $445M from October equity financing), providing runway into 2028. Resources will support clinical trials, manufacturing, and commercial preparation.
- **Triad Strategy**: Emphasized superiority (potential first anti-VEGF with a superiority label), market expansion (untreated NPDR patients), and adaptability (same workflow as current anti-VEGFs).

**【Q&A Highlights】**
- **Label Expectations**: CEO indicated confidence in a superiority label for wet AMD based on SOL-1 and flexibility in dosing intervals. SOL-R's head-to-head data against high-dose EYLEA may enhance competitive positioning.
- **DR Enrollment**: Sites for HELIOS trials overlap with wet AMD studies, leveraging experienced investigators. NPDR patients are motivated by the potential for a single injection lasting 12 months.
- **Endpoint Confidence**: Ordinal DRSS endpoint validated by HELIOS-1 results (all NPDR patients improved with a single dose). FDA-aligned design reduces regulatory risk.
- **SOL-X Insights**: Crossover patients from pulsatile therapy may not catch up due to fibrosis, underscoring the benefit of early AXPAXLI treatment.


Ocular Therapeutix, Inc. (OCUL) Q3 2025 Earnings Call Transcript

- **Superiority Trial Milestone:** SOL-1 rescue events align with 15-letter loss threshold, reinforcing AXPAXLI's durability claims.
- **Strategic Rescue Criteria Update:** SOL-R now uses >5-letter loss + ≥75µm CST increase, enhancing clinical relevance.
- **Long-Term Data Ambition:** Open-label extension study to compare delayed vs. immediate AXPAXLI treatment outcomes.
- **Financial Flexibility:** $390M cash balance supports clinical and commercial readiness, with 2028+ runway.
- **Market Differentiation:** Potential superiority label positions AXPAXLI for 6-12 month dosing, addressing unmet need for reduced treatment burden.

**【CEO Summary Section】**
- Ocular Therapeutix reported significant progress in its AXPAXLI clinical trials for wet AMD, with both SOL-1 (superiority trial) and SOL-R (non-inferiority trial) advancing on track.
- SOL-1 rescue events align with the 15-letter loss threshold, reinforcing data integrity. SOL-R updated rescue criteria to >5-letter loss + ≥75µm CST increase, reflecting real-world clinical practice.
- AXPAXLI aims for a superiority label, potentially offering dosing every 6-12 months, addressing the unmet need for reduced treatment burden.
- The company announced a long-term open-label extension study for both SOL trials to assess long-term durability and safety.
- Financial position remains strong with $390M in cash, supporting clinical and commercial readiness.

**【Clinical Trial Updates】**
- **SOL-1 (Superiority Trial):** 344 patients randomized, with exceptional retention. Rescue events under masking show consistent adherence to protocol, supporting confidence in durability claims.
- **SOL-R (Non-Inferiority Trial):** Enrollment complete, targeting 555 patients. Primary endpoint at week 56 (2 months post last injection) designed to minimize noise. Updated rescue criteria enhance clinical relevance.
- **Extension Study:** Patients from both trials will enter a 2-year safety follow-up, then transition to open-label AXPAXLI. Aims to compare delayed vs. immediate treatment outcomes.

**【Financial Position】**
- Q2 2025 cash balance: $390M, with $97M raised via ATM in June for flexibility.
- Expected runway into 2028, supporting SOL-1 (Q1 2026 readout) and SOL-R (H1 2027 readout).
- Strategic use of 505(b)(2) pathway for NDA submission, potentially shortening FDA review by 2 months.

**【Q&A Highlights】**
- **Rescue Criteria Change:** Driven by confidence in AXPAXLI's performance and desire for real-world alignment, not FDA requirement.
- **SOL-R Derisking:** 6-month screening/loading phase excludes unstable patients, enhancing trial reliability.
- **Commercial Readiness:** Investor Day (Sept 30) will detail global launch plans, including NPDR/DME expansion.
- **Competitive Positioning:** Superiority label could differentiate AXPAXLI from non-inferiority-based competitors, reducing reliance on pricing in prescribing decisions.

Ocular Therapeutix, Inc. (OCUL) Q2 2025 Earnings Call Transcript

- **Wet AMD Breakthrough**: AXPAXLI trials show potential for 6-12 month dosing intervals, addressing patient burden.
- **Efficient Trial Design**: SOL-1/SOL-R complementary approach reduces redundancy, accelerates timelines.
- **Financial Strength**: $392M cash runway supports 2028 operations, no 2025 capital raise needed.
- **Expansion Opportunity**: Diabetic retinopathy trials expected to begin in H1 2025, targeting 6.3M untreated NPDR patients.

**【CEO Opening Remarks】**
- 2024 was transformative, with AXPAXLI targeting wet AMD with potential 6-12 month dosing intervals.
- SOL-1 trial now includes redosing at weeks 52 and 76, enhancing durability data and label flexibility.
- SOL-R trial reduced from 825 to 555 patients, maintaining 90% statistical power while accelerating timelines.
- Expansion into NPDR and DME expected to begin in H1 2025 following FDA feedback.

**【Clinical Trial Updates】**
- **SOL-1**: Primary endpoint (36-week BCVA) unchanged, but masking extended to week 52 for durability insights. Topline data now expected Q1 2026.
- **SOL-R**: Non-inferiority margin set at -4.5 letters vs. 2mg aflibercept. Redosing strategy aligns with SOL-1, reducing redundancy.
- **Patient Recruitment**: SOL-1 randomized 344 subjects ahead of schedule; SOL-R reached 311 enrolled as of Jan 10, 2025.

**【Financial Position】**
- Cash balance of $392 million as of Dec 31, 2024, supporting operations into 2028.
- No intention to raise capital in 2025; funds allocated to wet AMD trials with flexibility for NPDR/DME expansion.

**【Q&A Highlights】**
- **Trial Design Efficiency**: Complementary SOL-1/SOL-R design reduces redundancy, maximizing data utility.
- **Redosing Strategy**: Week 52/76 dosing satisfies FDA safety requirements while demonstrating real-world flexibility.
- **Label Flexibility**: Potential for 6-12 month dosing label based on extended durability data.
- **NPDR/DME Pipeline**: FDA feedback expected H1 2025 to inform trial designs for underserved diabetic retinopathy patients.

Ocular Therapeutix (OCUL)-3 Mar 25-2024 Q4 Earnings call transcript

Ocular Therapeutix (OCUL)-14 Nov 24-2024 Q3 Earnings call transcript

Ocular Therapeutix (OCUL)-7 Aug 24-2024 Q2 Earnings call transcript

Ocular Therapeutix (OCUL)-7 Nov 23-2023 Q3 Earnings call transcript

Ocular Therapeutix (OCUL)-7 Aug 23-2023 Q2 Earnings call transcript

Ocular Therapeutix (OCUL)-8 May 23-2023 Q1 Earnings call transcript

Ocular Therapeutix (OCUL)-6 Mar 23-2022 Q4 Earnings call transcript

Ocular Therapeutix (OCUL)-8 Nov 22-2022 Q3 Earnings call transcript

Ocular Therapeutix (OCUL)-9 Aug 22-2022 Q2 Earnings call transcript

Ocular Therapeutix (OCUL)-10 May 22-2022 Q1 Earnings call transcript

Ocular Therapeutix (OCUL)-1 Mar 22-2021 Q4 Earnings call transcript

Ocular Therapeutix (OCUL)-9 Nov 21-2021 Q3 Earnings call transcript

Ocular Therapeutix (OCUL)-10 Aug 21-2021 Q2 Earnings call transcript

Ocular Therapeutix (OCUL)-6 May 21-2021 Q1 Earnings call transcript

Ocular Therapeutix (OCUL)-12 Mar 21-2020 Q4 Earnings call transcript

Ocular Therapeutix (OCUL)-5 Nov 20-2020 Q3 Earnings call transcript

Ocular Therapeutix (OCUL)-7 Aug 20-2020 Q2 Earnings call transcript

Ocular Therapeutix (OCUL)-8 May 20-2020 Q1 Earnings call transcript

Ocular Therapeutix (OCUL)-12 Mar 20-2019 Q4 Earnings call transcript

Ocular Therapeutix (OCUL)-12 Nov 19-2019 Q3 Earnings call transcript

Ocular Therapeutix (OCUL)-7 Aug 19-2019 Q2 Earnings call transcript

Ocular Therapeutix (OCUL)-10 May 19-2019 Q1 Earnings call transcript

Ocular Therapeutix (OCUL)-7 Mar 19-2018 Q4 Earnings call transcript

Ocular Therapeutix (OCUL)-7 Nov 18-2018 Q3 Earnings call transcript

Ocular Therapeutix (OCUL)-7 Aug 18-2018 Q2 Earnings call transcript

Ocular Therapeutix (OCUL)-8 May 18-2018 Q1 Earnings call transcript

Ocular Therapeutix (OCUL)-8 Mar 18-2017 Q4 Earnings call transcript

Ocular Therapeutix (OCUL)-7 Nov 17-2017 Q3 Earnings call transcript

Actual												-0.41	-0.64	-0.21	-1.21	-0.24	-0.11	0.03	-0.05	-0.16	-0.25	-0.31	-0.2	-0.39	-0.26	-0.0061	-0.35	-0.49	-0.26	-0.22	-0.29	-0.38	-0.39	-0.38
Forecast												-0.37	-0.3	-0.242	-0.1667	-0.2067	-0.21	-0.26	-0.234	-0.234	-0.222	-0.2383	-0.2533	-0.2633	-0.3014	-0.2871	-0.2963	-0.1925	-0.2213	-0.2427	-0.2539	-0.2944	-0.3567	-0.3715
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-10.81%	-113.33%	+13.22%	-625.85%	-16.11%	+47.62%	+111.54%	+78.63%	+31.62%	-12.61%	-30.09%	+21.04%	-48.12%	+13.74%	+97.88%	-18.12%	-154.55%	-17.49%	+9.35%	-14.22%	-29.08%	-9.34%	-2.29%

Actual	--	--	--	--	--	--	--	--	--	--	--	2.61M	1.57M	5.88M	7.35M	7.34M	11.72M	12.15M	12.31M	13.19M	12.27M	11.96M	14.08M	13.37M	15.19M	15.08M	14.80M	14.77M	16.44M	15.43M	17.08M	10.70M	13.46M	14.54M
Forecast	--	--	--	--	--	--	--	--	--	--	--	2.66M	1.50M	5.50M	7.73M	7.64M	10.82M	12.45M	13.94M	13.96M	14.25M	14.27M	13.53M	14.09M	14.62M	15.23M	15.70M	15.36M	15.85M	17.13M	17.15M	17.02M	13.46M	14.64M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1.75%	+4.68%	+6.81%	-4.93%	-3.86%	+8.25%	-2.42%	-11.71%	-5.52%	-13.91%	-16.16%	+4.01%	-5.10%	+3.84%	-0.97%	-5.74%	-3.83%	+3.74%	-9.94%	-0.42%	-37.15%	+0.02%	-0.63%

OCUL

OCUL fundamentals

OCUL Q3 2025 Earnings

Earnings Call

You can ask Aime

OCUL

OCUL fundamentals

OCUL Q3 2025 Earnings

Earnings Call

OCUL Earnings Call Summary for Q3/20258:00 AM on Nov 4, 2025

OCUL Earnings Call Summary for Q2/20258:00 AM on Aug 5, 2025

OCUL Earnings Call Summary for Q1/20257:00 AM on May 5, 2025

OCUL Earnings Call Summary for Q4/20248:00 AM on Mar 3, 2025

OCUL Earnings Call Summary for Q3/20248:00 AM on Nov 14, 2024

You can ask Aime